Watts A.M. et. al., Distinct Gene Expression Patterns between Nasal Mucosal Cells and Blood Collected from Allergic Rhinitis Sufferers., 10.1159/000489609, Int Arch Allergy Immunol. , Dec 18, 2018 ➔

Bommareddy P.K. et. al., MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation, 10.1126/scitranslmed.aau0417 , Science, Dec 12, 2018 ➔

Chon H.J. et. al., Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune checkpoint blockade., 10.1158/1078-0432.CCR-18-1932, Clin. Can. Res., Dec 11, 2018 ➔

Grabosch S. et. al., Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles, https://doi.org/10.1038/s41388-018-0581-9, Oncogene, Dec 05, 2018 ➔

Hillen L.M. et. al., Molecular profiling of Spitz nevi identified by digital RNA counting., 10.1097/CMR.0000000000000495., Melanoma Res., Dec 01, 2018 ➔

Christmas B.J. et. al., Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs, 10.1158/2326-6066.CIR-18-0070, Can. Immunol. Res., Dec 01, 2018 ➔

Gomes B. et. al., Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy, 10.1158/1535-7163.MCT-17-1104, Mol. Can. Ther., Dec 01, 2018 ➔

Tanaka H. et. al., Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer, 10.1158/1535-7163.MCT-17-1180, Mol. Can. Ther., Dec 01, 2018 ➔

Fenerty K.E. et. al., Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition, 10.1186/s40425-018-0445-4, J. Immunother. Cancer, Nov 29, 2018 ➔

Yu J.W. et. al., Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments, 10.1371/journal.pone.0206223, PLoS ONE, Nov 02, 2018 ➔

Du W. et. al., Sitravatinib potentiates immune checkpoint blockade in refractory cancer models, 10.1172/jci.insight.124184, JCI Insight, Nov 02, 2018 ➔

Szekely B. et. al., Immunological differences between primary and metastatic breast cancer., doi: 10.1093/annonc/mdy399., Ann. Oncol., Nov 01, 2018 ➔

Tan T.Z. et. al., Decoding transcriptomic intra-tumour heterogeneity to guide personalised medicine in ovarian cancer., 10.1002/path.5191, J. Pathol., Oct 30, 2018 ➔

Grellety T. et. al., Enhancing abiraterone acetate efficacy in androgen receptor-positive triple negative breast cancer: Chk1 as a potential target., 10.1158/1078-0432.CCR-18-1469, Clin. Can. Res., Oct 23, 2018 ➔

Dhage S. et. al., A genomic ruler to assess oncogenic transition between breast tumor and stroma, 10.1371/journal.pone.0205602, PLoS ONE, Oct 16, 2018 ➔